List of Aspruzyo Sprinkle drug patents
Aspruzyo Sprinkle is owned by Spil.
Aspruzyo Sprinkle contains Ranolazine.
Aspruzyo Sprinkle has a total of 2 drug patents out of which 0 drug patents have expired.
Aspruzyo Sprinkle was authorised for market use on 28 February, 2022.
Aspruzyo Sprinkle is available in granules, extended release;oral dosage forms.
The generics of Aspruzyo Sprinkle are possible to be released after 24 January, 2038.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10898444 | SPIL | Extended release multiparticulates of ranolazine |
Jan, 2038
(14 years from now) | |
| US11510878 | SPIL | NA |
Jan, 2038
(14 years from now) | |
Drugs and Companies using RANOLAZINE ingredient
Market Authorisation Date: 28 February, 2022
Treatment: NA
Dosage: GRANULES, EXTENDED RELEASE;ORAL
ASPRUZYO SPRINKLE family patents
2
United States
1
India
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic